Possible attenuation of gout risk by SGLT-2 inhibitors in patients using thiazide and loop diuretics.

Expert Rev Endocrinol Metab

Department of Pharmacology & Therapeutics, College of Medicine & Health Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain.

Published: May 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://dx.doi.org/10.1080/17446651.2025.2480695DOI Listing

Publication Analysis

Top Keywords

attenuation gout
4
gout risk
4
risk sglt-2
4
sglt-2 inhibitors
4
inhibitors patients
4
patients thiazide
4
thiazide loop
4
loop diuretics
4
attenuation
1
risk
1

Similar Publications

Gouty arthritis (GA) is an inflammatory arthritic disorder that is characterized by intense, acute inflammatory responses, such as synovitis and arthritis that occur due to articular deposition of monosodium urate (MSU) crystals. This study has compared the therapeutic potentials of either Berberine (BERB) or Paracetamol (Para) on MSU-induced inflammation in rat model of Gouty arthritis (GA). GA was induced by "intra-articular" injection of MSU suspension (20 mg/ml) inside the knee joint of the rat's right limb.

View Article and Find Full Text PDF

Background: Inflammation is a vital biological defense mechanism, yet uncontrolled or prolonged inflammation can cause tissue damage. The NLRP3 inflammasome, a central component of innate immunity, drives inflammation by activating caspase-1 and promoting the release of cytokines like IL-1β. Monosodium urate (MSU) crystals are potent NLRP3 inflammasome activators implicated in diseases such as gout.

View Article and Find Full Text PDF

Aims: Gout is associated with increased ischaemic cardiovascular disease (CVD). The effects of allopurinol and colchicine on CVD risk remain debated. This study aims to investigate the interplay between these factors.

View Article and Find Full Text PDF

Hyperuricemia, associated with gout and chronic kidney disease, underscores the need for novel therapies. Recent studies suggest that the gut microbiota may play a role in the pathogenesis of HUA, with certain probiotics demonstrating potential in reducing urate levels. Notably, Limosilactobacillus fermentum M5e exhibits exceptional in vitro uric acid degradation, yet its in vivo mechanisms remain unexplored.

View Article and Find Full Text PDF

Background: Interleukin-1 receptor-associated kinase 4 (IRAK4) is a pivotal mediator of toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling, critically involved in innate immune activation and pro-inflammatory cytokine production. Dysregulated IRAK4 activity contributes to chronic inflammation in both immune and non-immune cells. In this study, we evaluated the immunomodulatory potential of a selective IRAK4 inhibitor on monosodium urate (MSU) crystals-stimulated macrophages and xanthine-challenged HepG2 cells to assess its therapeutic potential.

View Article and Find Full Text PDF